Picture loading failed.

Anti-MS4A1;CD3E therapeutic antibody (Pre-made Plamotamab biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Plamotamab (XmAb®13676) is a tumor-targeted bispecific antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3), which is currently in a Phase 1 clinical study for the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-446-1mg 1mg Inquiry
GMP-Bios-ab-446-10mg 10mg Inquiry
GMP-Bios-ab-446-100mg 100mg Inquiry
GMP-Bios-ab-446-xmg >100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Anti-MS4A1;CD3E therapeutic antibody (Pre-made Plamotamab biosimilar,Bispecific Mixed mAb and scFv)
INN Name Plamotamab
FormatBispecific Mixed mAb and scFv
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2018
Year Recommended2019
Conditions Approvedna
Conditions ActiveB-cell lymphoma;Chronic lymphocytic leukaemia;Non-Hodgkin's lymphoma
Conditions Discontinuedna
Development Techna